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Low-voltage  activated  T-type  channels  contribute  significantly  to  signal  transmission  in
ascending pain pathway. Their electrophysiological and biochemical properties allow them to
modulate neuronal excitability and neurotransmitter release. Alterations of electric currents
associated with a number of neuronal disorders, including neuropathic pain and epilepsy, have
been linked to this subtype of calcium channel, suggesting its prominent role in modulation of
neuronal response to various  noxious stimuli.  Multiple diseases, such as diabetes, cancer or
chronic nerve injury, are accompanied by painful neuropathic conditions. Specific inhibitors
of  T-type  channels  have  been demonstrated  to  alleviate  symptoms of  neuropathic  pain  in
mouse models, showing their potential for development of novel type of drugs possibly more
effective than traditional analgesics, which exhibit minor effect in neuropathic pain treatment. 
Key words: calcium channels, T-type channels, neuropathic pain, nociception, neuronal 
excitability, analgesics, diabetes
Abstrakt
Nízkonapěťově  aktivované  iontové  kanály  se  významně  podílí  na  přenosu  signálu  ve
vzestupné dráze  bolesti.  Jejich  elektrofyziologické  a  biochemické vlastnosti  jim umožňují
regulovat  neuronální  excitabilitu  a  uvolňování  neurotransmiterů.  Změny  v  elektrických
proudech spojovaných s nervovými poruchami včetně neuropatické bolesti a epilepsie, jsou
spojovány s tímto subtypem vápenných kanálů, naznačujíc tak jejich zásadní roli v modulaci
neuronální  odpovědi  na  různé  obtěžující  stimuly.  Povícero  nemocí,  jako  třeba  cukrovka,
rakovina nebo chronický úraz nervu,  jsou doprovázeny bolestivými neuropatickými stavy.
Specifické inhibitory T-typu kanálů vykazují  zlehčující  účinky na neuropatickou bolest  ve
zvířecích  modelech,  ukazujíce  tak  jejich  potenciál  k  vývoji  nových  typů  léků  možná
učinnějších než tradiční analgetika, která vykazují malý efekt při léčbě neuropatické bolesti.
Klíčová  slova:  vápenné  kanály,  kanály  T-typu,  neuropatická  bolest,  nocicepce,  neuronální
excitabilita, analgetika, cukrovka
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The ability to experience pain has its important role in our lives. Pain warns us when a potentially
harmful event occurs or is  about to occur,  and commences a coordinated reflex and behavioral
responses  which  serve  as  an  important  protective  mechanism.  It  is  a  result  of  a  physiological
activation of nociceptive cells in peripheral tissues such as skin or visceral organs. This nociceptive
pain is usually responsive to traditional pain management drugs and its protective function further
continues even in chronic pain, in which case hypersensitivity to pain in inflamed areas protects us
from further damaging by promoting careful behavior concerning the affected tissue.
However,  pain may also arise without adequate stimulation of peripheral nociceptive pathways,
generated  by  untypical  activity  of  nociceptive  neurons.  This  type  of  pain  is  referred  to  as
neuropathic pain and can be defined as “pain arising as a direct consequence of a lesion or disease
affecting  the  somatosensory system.”  (Treede  et  al.  2008) This  definition  distinguishes  it  from
physiological  inflammatory  pain  or  pain  caused  indirectly  by  other  neurological  disorders.
Neuropathic pain is often connected with several medical conditions, for example a spinal cord
injury,  multiple  sclerosis,  autoimmune  diseases,  diabetes  or  cancer  (Marchettini  et  al.  2006).
Symptoms  of  neuropathic  pain,  such  as  dysesthesia  (abnormal  sense  of  touch),  hyperalgesia
(increased sensitivity to painful stimuli) and allodynia (painful response to normally not painful
stimuli), often lead to poor sleep, depression, and anxiety of patients (Turk et al. 2010). Neuropathic
pain is  also a  relatively largely spread disease,  affecting up to  7% of the European population
(Bouhassira et al. 2008). This, combined with the fact that traditional pain management drugs do
not exhibit sufficient results when used to treat neuropathic pain, leads to the necessity of novel
drugs development (Finnerup et al. 2015).
One of the possible targets for those drugs are low-voltage activated calcium channels known as T-
type calcium channels. Electric currents associated with these channels have been demonstrated to
appear  in  mouse  models  of  absent  epilepsy  and  neuropathic  pain.  Further  research  followed,
discovering that these channels indeed affect these two diseases. 
This review focuses on T-type channels and how they affect physiology of neuropathic pain. Firstly,
basic concepts behind pain signalling will be addressed and then the voltage-gated calcium channels
will be focused on. Finally, the role of T-type channels in pain signalling will be demonstrated,
followed by an overview of their involvement in neuropathic pain states. 
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Pain pathway
Anatomical review of pain pathway
The first step in ascending pain pathway is mediated by the population of neuronal cells called
nociceptors. Their bodies are located in dorsal root ganglia (DRG) and in the trigeminal ganglion
for the body innervation and for the face respectively, and by being pseudounipolar neurons they
have two axons. The peripheral axon innervates different body parts such as skin, internal organs,
joints or muscles, whereas the central axon conducts signal from the body of nociceptor to the
second order neuron located in the dorsal horn (DH) of a spinal cord. These cells respond to a wide
spectrum of noxious stimuli like heat, cold, inflammation and chemicals, and are usually excited
when stimuli from their target location is strong enough to overcome their threshold of excitation,
so  that  they  can  signalize  a  potentially  harmful  situation.  Sensitivity  of  nociceptive  fibers  to
different stimuli is represented by their modality (range of external signals that a specific population
of cells in the fiber is sensitive to). Based on a distinctive type of fiber, nociceptors can be further
divided into at least two distinct subpopulations which have different morpholigical, physiological
and electrophysiological properties (Almeida et al. 2004). 
The Aδ-nociceptors have thin myelinated axons and thus they provide a well-localised fast response
to noxious stimuli (speed<30 m/s). They are sensitive to heat and mechanical inputs so they are
sometimes referred to as AMHs (A-fiber mechano-heat). AMHs are further subdivided into the type
I AMHs, which exhibit a high heat threshold and a lower mechanical threshold, and the type II
AMHs, which have the opposite properties: a low heat threshold and a high mechanical threshold.
The fast response to heat is mostly mediated by the type II AMHs. In contrast, the Type I fiber more
likely mediates the first pain provoked by a pinprick and other intense mechanical stimuli.(R.D.
Treede, R.A. Meyer 1998)
The C-type nociceptors are also a heterogenous population of neurons. Most of them are polymodal
unmyelinated fibers responsive to heat and mechanical stimuli. As a result of unmyelinated axons,
their  conduction speed is much slower (1 m/s) and responsible for the “second pain” sensation
appearing some time after painful stimulation (Van Hees & Gybels 1981)
Both types of these fibers also function as mechanoreceptors in a non-nociceptive way, mostly as
receptors of light touch like light pressure of a blunt object or a touch of fur. Another group of
neuronal fibers which is largely ignored when talking about pain is Aβ fibers. Most of Aβ fibers are
considered  Aβ-LTMs with a non-nociceptive function. The abbreviation LTM means low-threshold
mechanoreceptor and is widely used. The LTMs' role in pain signalling is discussed as they are
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generally viewed only as primary “light touch” receptors.  However,  certain transduction speeds
attributed to Aδ signalling are, by some experts, considered much higher than expected and some
other findings also show that nociceptive function of Aβ neurons could be more important than it
was thought before. (Djouhri & Lawson 2004) 
Different morphological properties of nociceptive cells in DRG are used as a tool to determine the
neuron's function. Somas of Aδ- and C-type thin axon neurons associated with nociceptive function
exhibit a smaller diameter (<31μm). On the other hand,  Aβ-fiber neurons usually have a larger
diameter (31-45μm) resulting in their medium-size classification, and their function can be both
mechanoreceptive and nociceptive (Lee et al. 1986).
Central  axons of primary afferent nociceptive fibers project to dorsal  horn neurons in different
laminae I, II and V. However, their central processes terminate mostly in superficial layers (lamina I
and II). These laminae create major output of the dorsal horn to the CNS; mostly thalamus, but also
medulla and brain stem, where they innervate specific locations. Thalamus then serves as a hub to
connect different cortical areas which allow us to perceive pain. (Brooks & Tracey 2005)
Ion channels involved in pain pathway
Studies of the transient receptor potential (TRP) family of ion channels helped to establish their
distinctive  function  and  their  role  as  nociceptors.  More  than  30  members  of  the  family  were
identified and their  importance has been indicated in many biological processes  (Ramsey et  al.
2006) However, the greatest attention is given to three types of these channels: TRPV1, TRPA1 and
TRPM8, as they are closely related to pain signalling.
The  most  studied  member  of  the  family is  the  TRPV1 channel.  This  receptor  is  activated  by
vanilloids like capsaicin. When exposed to capsaicin or its agonists, and also at negative membrane
potential, the channel opens, resulting in an influx of calcium and sodium, thereby depolarizing the
cell.  In this manner,  the channel responds to chemical impulses  (Hui et  al.  2003). The TRPV1
channel also increases its activity when subjected to elevated extracellular proton concentrations,
thereby  increasing  pain  sensation  (Jordt  et  al.  2000).  Another  way  in  which  the  channel  is
modulated  is  via  heat.  Experiments  showed  that  when  at  holding  potential  of  -60  mV  and
temperature above 43°C,  the  inward current abruptly increases and gives the channel a thermal-
sensing modality (Tominaga et al. 1998).
TRPM8 is a ion channel responsible for cooling and menthol sensation. It induces cold stimuli
below 26°C and at temperature of 15°C, it generates noxious stimuli peaking at 8°C. An interesting
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property of  this  channel  is  that  it  is  probably never  co-expressed  with  the  heat-activated  TRP
channel TRPV1, calcitonin gene-related peptide (CGPR) or isolectin B4 binding (Peier et al. 2002)
The TRPA1 channel responds to a wide range of stimuli in apparently unrelated modalities such as
thermal, mechanical and chemical, which in turn activate nociceptive neurons. Research shows that
TRPA1 affects  mechanotransduction and pain signalling,  but many aspects of this  topic  remain
unclear (Garrison & Stucky 2011).
ATP is  known to play a  crucial  role  in almost  all  intracellular processes,  however,  it  has been
demonstrated that it can also contribute to pain signalling. ATP is released from damaged cells and
can evoke nociception via P2X ionotropic receptors which are selectively expressed in small and
medium DRG cells (Gu & MacDermott 1997). 
Acid-gated  ion  channels,  also  known as  proton-gated  ion  channels  or  ASICs  (acid-sensing  ion
channels),  are  gated by pH reductions  and probably responsible  for pain sensation in  inflamed
tissues, as acidification is one of the results of inflammatory processes. They are expressed in small
DRG cells, indicating their connection to the nociception (Chen et al. 1998).
After  the  primary  signal  transduction  by  the  thermal,  chemical  or  mechanical  stimuli,  signal
conduction is carried by a variety of ion channels. The most important channels involved in the
conduction of the signal come from the family of sodium channels. The primary role of voltage
activated sodium channels is to generate high threshold spikes that convey nociceptive signals to the
dorsal  horn.  There  are  ten  variants  identified,  each  encoded by a  different  gene  with  a  highly
conserved α-subunit and named accordingly Nav1.x. Some of these, namely Nav1.7 and Nav1.8, play
a major role in the conduction of the pain signal (Waxman et al. 1999). 
Tetrodoxin (TTX)-resistant Nav 1.8 is implicated as crucial for the pain conduction as the knockout
exhibits selective disorders in pain pathways (Akopian et al. 1996). An abnormal activity of (TTX)-
sensitive Nav1.7 leads to a number of human pain disorders. Gain-of-function mutations of Nav1.7
result in primary erythermalgia and a paroxysmal extreme pain disorder, whereas people without
functional Nav1.7 channel exhibit a rare disorder of total insensivity to physical pain. Studies also
show that Nav1.7 is up-regulated in a variety of animal models of inflammatory pain (Drenth et al.
2007). As there are 10 types of sodium channels of different distributions and functional properties,
it can be safely assumed that their influence on overall pain management is substantial, making
them a desirable target for analgesics (Wood et al. 2004).
Multiple  voltage-gated  potassium  channels  are  widely  expressed  in  DRG,  some  of  them
preferentially located in small DRG nociceptive cells and cells responding to the capsaicin. It also
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appears  that  at  least  some  of  them  occur  in  nerve  endings,  as  potassium  channel  inhibitors
administered to nerve endings, not axons, induced continuous discharges in most Aα, Aδ, and C-
fibers (Gold et al. 1996).  
Voltage-gated calcium channels
Contribution to signal transmission
Different types of Ca2+  channels are widely expressed through many different cell types and serve
multiple purposes in signalling and cell regulation. The Ca2+   influx into the cell causes membrane
depolarization  at  threshold  and  subthreshold  levels  and  it  participates  in  an  electrical  signal
conduction. Additionally, an increased concentration of calcium ions in cytoplasm leads to a variety
of cellular responses as the Ca2+   ions act as an important second messenger, causing a cellular
response  depending  on  a  specific  cell  type.  For  example,  in  cardiac  and  smooth  muscles  an
increased activity of  voltage-gated Ca2+ channels (VGCCs) initiates a muscle contraction. Ca2+  ions
activate ryanodine-sensitive receptors in the membrane of sarcoplasmic reticulum, which causes a
Ca2+  efflux to the cytoplasm. (Reuter 1979)  
In  transverse tubules  of  skeletal  muscle,  VGCCs directly interact  with ryanodine-sensitive Ca2+
channels  of  sarcoplasmic  reticulum,  causing  muscle  contraction.  When  impulses  activating  the
muscle contraction come in a close succession, a cytoplasmic concentration of Ca2+ further increases
and regulates the force of contraction, eventually leading to tetanus. (Catterall et al. 1991)   VGCCs
also mediate  secretion in  endocrine cells  (Yang & Berggren 2006) and generally regulate  gene
expression, enzyme activity and biochemical processes in many cell types.  (Flavell & Greenberg
2008) Because of their influence on the presynaptic neurotransmitter release and calcium currents
affecting  polarization  of  the  membrane,  activity  of  these  channels  is  crucial  for  the  signal
conduction in neuronal signalling. 
Voltage-gated  Ca2+ channels  are  traditionally  divided  into  several  categories  based  on  their
physiological  and pharmacological  properties.  We distinguish N-,  L-,  P/Q-,  R-  and T-  types  of
channels, each blocked by a different specific blocker and with a specific function and expression.
(Table 1) These can be further divided into two main classes based on their activation threshold.
N-, L-, P/Q- and R- belong to the family of high-voltage activated (HVA) calcium channels and
typically exhibit higher activation thresholds, larger conductances and variable inactivation kinetics.
On the other hand, T- type channels have a much lower activation threshold, close to the resting
potential of the cell, and thus called low-voltage activated channels (LVA). They also exhibit lower
conductance and fast inactivation kinetics. (Tsien et al. 1991)
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Table 1. Physiological function and pharmacology of voltage-gated calcium channels. Table from (Catterall et al. 2005)
The N-type channels were found to be highly expressed in presynaptic terminals of nociceptive
DRG cells. This led to an assumption that their activity is somehow connected to pain signalling
(Chaplan et al. 1994). Channels open in response to action potential,  thereby causing a calcium
influx and a rise of the  intracellular concentration of Ca2+  ions.  The concentration of  Ca2+  ions
heavily affects  the rate of neurotransmitter  release and this  was proved by the following study.
Short-term synaptic  depression occurs  during  high synaptic  activity,  meaning that  a  number  of
readily-releasable  vesicles  is  getting  lower,  thus  attenuating  neurotransmitter  release. The  Ca2+
modulates vesicle budding and filling only in a close vicinity of Ca2+  channels (Wang & Kaczmarek
1998).  This spatial requirement suggested an interaction between a calcium channel and synaptic
proteins. Studies indeed showed that certain types of N-type HVA channels share a synaptic protein
interaction  (synprint)  site  in  a  linker  between domains  I  and II, which allows  such interaction
between the channel and SNARE proteins like syntaxin-1A, SNAP-25 and synaptotagmin (Sheng et
al.  1994) (Zamponi  2003).  This  turned  out  to  be  a  cross-talk,  since  these  synaptic  proteins
reciprocally  inhibit an  activity of  N-type calcium  channels  (Catterall  et  al.  1999),  making  the
regulation of nociceptive signaling a far more complex process. 
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Channel Current Localization Specific antagonists Cellular functions
Cav 1.1 L Skeletal muscle; transverse tubules Excitation-contraction coupling
Cav 1.2 L
Cav 1.3 L
Cav 1.4 L Neurotransmitter release from photoreceptors
Cav 2.1 P/Q ω -Agatoxin IVA 
Cav 2.2 N ω -Conotoxin-GVIA 
Cav 2.3 R Neuronal cell bodies and dendrites SNX-482 Repetitive firing; dendritic calcium transients
Cav 3.1 T None Pacemaking; repetitive firing
Cav 3.2 T None Pacemaking; repetitive firing




Cardiac myocytes; smooth muscle; 





Excitation-contraction coupling; hormone release; 
regulation of transcription; synaptic integration
Endocrine cells; neuronal cell bodies 
and dendrites; cardiac atrial myocytes 





Hormone release; regulation of transcription; 
synaptic regulation; cardiac pacemaking; hearing; 
neurotransmitter release from sensory cells
Retinal rod and bipolar cells; spinal 




Nerve terminals and dendrites; 
neuroendocrine cells
Neurotransmitter release; dendritic Ca transients; 
hormone release
Nerve terminals and dendrites; 
neuroendocrine cells
Neurotransmitter release; dendritic Ca transients; 
hormone release
Neuronal cell bodies and dendrites; 
cardiac and smooth muscle myocytes
Neuronal cell bodies and dendrites; 
cardiac and smooth muscle myocytes
T-type channels were also described as modulating nociceptive signalling, but to further expand on
their function, the structure and characteristics of VGCCs have to be introduced.
Structure of voltage-gated calcium channels
The analysis of VGCCs isolated from rabbit sceletal muscle transversal tubules showed that  L-type
channels consist of five subunits designated as α1, α2, γ, and δ.  This analysis led to a model where
190kDa α1 subunit associates with a 170 kDa disulfide-linked α2δ dimer, a 55kDa intracellular
phosphorylated β subunit, and a 33 kDa transmembrane γ subunit.(Takahashi et al. 1987)
The α1 was identified as a pore-forming unit of the channel. The subunit itself has around 2000
aminoacids in length and a structure similar to the pore-forming unit of previously characterized α
subunit of the potassium channel. Each of four repeated domains I-IV consists of six membrane α-
helical segments S1-S6. The domains are connected together by cytoplasmic regions and also N-
and C- termini of protein are located in cytoplasm. (Tanabe et al. 1987) (Figure 1)
The γ subunit is only present in L-type VGCCs, other HVA channels do not contain this subunit and
only consist of α1, α2, and δ subunits. T-type channels are specific for the absence of any other
regulatory domain and are formed by a single α1 subunit. However, it seems that the α1 subunit is
responsible for most of the pharmacological and electrophysiological diversity.  (Hofmann et al.
1994)
Figure 1 Subunit structure of Cav1 channels. Image taken from (Catterall et al. 2005)
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As the identification and description of genes coding α1 subunit continued, new terminology based
on a sequential identity between them was adopted. Nowadays, ten genes associated with VGCC
are known and they are named CavX.Y, where X represents the number of a subfamily and Y the
subtype of a channel in an order of their discovery. This nomenclature, common in voltage-gated
ion channels, arises from the nomenclature defined for more explored sodium channels. (Table 1)
(Goldin et al. 2000)
T-type calcium channels
Molecular Physiology of T-type channels
There are three known members of the T-type subfamily with distinct functional properties, Cav3.1,
Cav3.2 and Cav3.3. As mentioned above, they consist of a single  α1 which than determines their
functional properties. Subtypes of the T-type calcium channels are widely expressed in particular
neural tissues in a specific pattern, suggesting that each of them serves a slightly different purpose
(Talley et al. 1999).  
Precise measurements of their activation kinetics and conductances were made possible by a wider
spread of cloning methods as the researchers were able to express defined channels of a single type.
DNA of Cav3.1 was isolated from a rat brain and expressed (and the current associated with the
channel consequently measured) for the first time in Xaenopus oocytes (Perez-Reyes et al. 1998),
Cav3.2 DNA originated from a human and it was expressed in HEK-293 cells (Cribbs et al. 1998),
and finally, Cav3.3 channel DNA was isolated from a rat brain and expressed in Xaenopus oocytes
(Lee et al. 1999). 
The  T-type  channels  activate  in  a  low membrane  potentials,  so  small  positive  changes  in  the
membrane potential can open them. At the certain membrane potentials there is also an overlap
between open, closed and inactivated state. Under these specific conditions a “window current”
appears. A certain fraction of channels is opened, whereby basal influx of calcium ions can occur
(Fig 2) (Stephen R. et al. 1997). These currents are associated with a number of thalamic functions,
for example during NREM phase of sleep (Crunelli et al. 2006) . Another important attribute of T-
type channels is their ability to burst-fire, which occurs during generation of low-threshold spikes
(LTS). For LTS patterns to appear, the membrane has to be hyperpolarizated below -70 mV. At this
potencial, the T-type channels start to de-inactivate. De-inactivation of LTS takes about 200ms (half
of the channels recover after 100ms) and thus T-type channels may function as pacemaker(Perez-
Reyes 2003). The LTSs have been also connected to epilepsy in mouse models(Tsakiridou et al.
1995)
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Figure 2. Key functional properties of T-type calcium channels. (a) Simplified scheme of T-type channel gating. At
hyperpolarized voltages, channels are in the closed state(C). Membrane depolarization triggers a transition towards the
open state (O), which allows calcium entry. Prolonged depolarization causes channels to enter theinactivated state (I),
from which channels can be recovered by hyperpolarization. (b) Typical family of whole cell T-type calcium currents,
elicited  by stepping  from a  holding  potential  of  -110  mV to  a  series  of  incremental  depolarizations.  (c)  Voltage
dependence  of  activation  and  inactivation.  Note  that  at  a  typical  neuronal  resting membranepotential  (-75  mV) a
significant fraction of the channels are inactivated. Also note the overlap of the activation and inactivation curves,
which gives rise to a window current(i.e. a voltage range where T-type channels can be tonically active). (d) Rebound
bursting illustrated by the tonic firing of a habenular neuron. In  response to amembrane hyperpolarization, T-type
channels  are  recovered  from  inactivation,  and  their  subsequent  activation  in  response  to  a  return  to  the  resting
membrane potential triggers an action potential burst. Image taken from (Iftinca & Zamponi 2009)
The voltage dependencies and rates of channel activation, deactivation, inactivation and recovery
from inactivation, define an ability of an individual channel subtype to conduct calcium. The Cav3.1
and Cav3.2 both have a slightly different attributes compared to Cav3.3 isoform: both open at the
membrane  potential  around -10  mV lower  and  both  also  inactivate  at  the  membrane  potential
around -5mV lower, which result in the requirement of more hyperpolarized membrane to reach de-
inactivation potential needed for the activation of those channel isoforms(Chemin et al. 2002). The
same goes for the activation and deactivation of the channel, Cav3.3 kinetics in these apects are also
much  slower.  On  the  contrary,  the  speed  of  deactivation  is  the  fastest  in  Cav3.3.  When  the
depolarization event occurs,  Cav3.1 and  Cav3.2 activate first, followed by Cav3.3, then inactivate.
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During repolarization, the Cav3.3 channels close the quickest thanks to their deactivation kinetics.
Recovery kinetics  are  different  entirely,  Cav3.1  being the  fastest  and Cav3.2  being  the  slowest
(Figure 3) (Kozlov et al. 1999).
Figure 3. Basic biophysical properties of T-type calcium channels. (A) Representative currents, (B) conductance and 
inactivation profiles, (C) representative deactivating currents and (D) recovery from inactivation properties of cloned 
CaV3.1, CaV3.2 and CaV3.3 expressed in HEK293 cells (E) Table summarizing mean kinetic properties of the three T-
subtypes at representative voltages. Image taken from (Cain & Snutch 2010)
Role of T-type channels in pain signalling
Low-voltage activated T-type channels have been considered significant for the excitation of DRG
neurons for a long time as their presence in the DRG was demonstrated more than 30 years ago
(Carbone & Lux 1984).  As these channels open thanks to small depolarizations of a membrane,
calcium influx into the cell can trigger activation of other voltage-gated channels activated at the
slightly higher membrane potentials. In situations like that, T-type channels serve as an amplifier:
originally a tiny change in the membrane polarization can cause cascade reaction resulting in a
formation of action potential. This subthreshold excitations connected to the T-type channels were
observed  in  a  medium-size  DRG  cells  (associated  with  either  nociceptive  or  mechanosensory
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function)  (White et al. 1989). Another study showed that small DRG cells expressing the T-type
currents are also sensitive to capsaicin, implicating a role of T-types in nociception (Cardenas et al.
1995).  The  after-depolarizing  potential,  which  is  important  for  setting  a  threshold  for
neurotransmitter  release,  also occurs in T-current  rich cells.  This,  together with a subthreshold-
depolarization  potency of  the  T-type  calcium channels,  implies  that  T-types  are  at  least  partly
responsible  for  setting  the sensitivity to  nociceptive  stimuli  (Nelson et  al.  2007).  These results
showed that T-types are likely to contribute to the excitability of DRG neurons tightly connected to
the pain signalling.
The T-type calcium channels also generate Ca2+  influx into the cell, which may in turn lead to the
vesicle exocytosis.  Since currents transduced by T-type channels are much lower than usual for
other types of calcium channels, significance of T-type contribution was long disputed. However, T-
type channels were associated with the low-threshold exocytosis  in dorsal horn laminae I and II,
where they generate “spontaneous” small excitation potentials (Bao et al. 1998). Since the T-types
lack synprint motif present in the Cav2.1 and Cav2.2 N-type channels, a distinctive mechanism for
the  low-threshold  exocytosis  had  to  be  proposed  because,  as  mentioned  earlier,  close  vicinity
between the channel and a budding vesicle is required. A recent study shows that syntaxin-1A is
recruited to the Cav3.2, therefore promoting needed interaction. As opposed to the N-type channels,
this  interaction  is  facilitated  by  carboxyl-terminal  domain,  suggesting  a  different  interaction
principle.  Moreover,  this  interaction  decreases  channel  availability  by  shifting  the  steady-state
inactivation towards the more hyperpolarized potentials, resulting in a similar effect on the channel
as it has on Cav2.1 and Cav2.2 N-type channels. (Weiss et al. 2012).
As the DRG nociceptive neurons are primarily connected to dorsal horn neurons in laminae I and II,
research of the possible modulation of nociception by T-type channels seemed prospective. Indeed,
a study mentioned earlier registered miniature excitatory postsynaptic currents (mEPSC) in these
layers, which were caused by the T-type channels and resulted in the neurotransmitter release (Bao
et al. 1998).  However, a later study examining these currents in the DH discovered that besides
mEPSCs, there are miniature excitatory postsynaptic currents (mIPSC) present as well. The authors
demonstrated that specific pharmacological inhibition of the  Cav3.2 T-channels by a novel drug
TTA-P2 reduces mEPSC frequency in nociceptive projection neurons in the superficial laminae of
the DH, while mIPSCs are not affected. This discovery indicates that activation of the presynaptic
Cav3.2 channels  may result  in  a  selective  increase of  excitatory neurotransmitter  release at  the
nociceptive spinal synapse and consequently fine tune the postsynaptic excitability. Although there
is not much known about the precise principles behind this kind of regulation, because multiple
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HVA channels also contribute to the calcium influx and many other variables are in play, this study
opened new prospective research field for the T-type channels involvement in pain signaling (Jacus
et al. 2012).
However, it was hard to prove a role of T-types in nociception for a long time due to the absence of
selective T-type channel inhibitor.  A study showed that injection of reducing agents L-cysteine or
DTT (dithiothreitol) up-regulated the activity of DRG neurons and resulted in hyperalgesia. On the
other hand, an oxidizing agent, 5,5′-dithio-bis-(2-nitrobenzoic acid) (DTNB) reversed up-regulation
and restored the normal phenotype. Hyperalgesia caused by reducing agents was also reversed by
the T-type channel blocker mibefradil, thus proving the involvement of the channel. Interestingly,
this  T-type  channel  blocker  also  caused  a  decreased  pain  sensation  in  non-hyperalgaic  rats
(Todorovic et al. 2001).   Results of this study were expanded on by a discovery of “T-rich” cells.
When subjected to the L-cystein, this subpopulation of small DRG nociceptive cells manifested
lowered  threshold  of  excitability and  also  started  to  burst  fire.  Electrophysiological  recordings
showed that reason for this different excitability lied in a shift of the T-type channels gating, thus
proving their direct involvement in the nociception for the first time (Nelson et al. 2005). 
Another challenge was to prove an essential role of the Cav3.2 subtype in nociception. This channel
was known to be expressed more than the other two subtypes in DRG (Talley et al. 1999). Final
proof of the prominent Cav3.2 subtype involvement in pain signalling was laid down by in vivo
silencing  of  mRNA.  Rat  conditional  knockdowns  were  induced  by  administering  anti-sense
oligodeoxynucleotides  of  each  Cav3  subtype.  Antisense  silencing  of  Cav3.2  showed  a  great
reduction  of  corresponding  mRNA,  protein  expression  and  T-type  currents  in  DRG,  and  also
resulted in major anti-nociceptive, anti-hyperalgesic and anti-allodynic effects. This study gave a
first  direct  evidence of Cav3.2 involvement  in  nociception  (Bourinet  et  al.  2005).  Results  were
further supported by a study done on mice lacking the  Cav3.2 gene altogether. Effects similar to
those of the previous study were observed. (Choi et al. 2007)
Evidence  also  shows  that  T-type  channels  are  regulated  by  G-protein  βγ  subunits  functionally
connected with various G-protein-coupled receptors. The G-protein activated kinases interact with a
linker between domain II and III, which serves them as a target site. This linker is therefore subject
to the modulation by different hormones, further expanding the ways of T-type current regulation,
possibly leading to the development of new drugs targeting T-type channel.
Protein kinase A (PKA) has been suggested to up-regulate a function of the  Cav3 channels via
known deregulations of T-type currents generated by serotonin, cAMP and PKA inhibitors in the rat
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adrenal glomerulosa cells (Lenglet et al. 2002), later proven by (Chemin et al. 2007).  Serotonin
caused  enhanced  activity  of  the  Cav3.2  in  Xaenopus oocytes  when  coexpressed  with  5-HT7
serotonin receptor, which has its downstream effector in PKA. A target site for the PKA and other
kinases  was  established  by  a  chimeric  construct:  instead  of  the  original  Cav3.2  II-III  linker,
construct contained PKA-insensitive Nav1.4 linker. The protein product of the construct was not
sesitive to the PKA, indicating the II-III linker as the target site  (Kim et al. 2006). On the contrary,
dopamine inhibits the T-type currents in the bass retinal horizontal cells  (Pfeiffer-Linn & Lasater
1993).
Same as for PKA, protein kinase C (PKC) up- and down-regulates the function of T-type channels.
Angiotensin II (Rossier et al. 1995)and endothelin-1 (Furukawa et al. 1992) inhibit T-type channels,
cobrotoxin (Zhang et al. 2011) and neurokinin 1 (Rangel et al. 2010) rather enhance function of T-
types through different modification of the PKC. Most of these experiments were done on a mouse
model neurons from different neuronal tissues, strongly suggesting that PKA and PKC regulatory
effects on the T-type currents vary through different cell types, protein interactions and G-proteins
involved in the regulatory pathways.
The lysophospatidic acid (LPA) acts through the activation of LPA GPCRs connected with Rho
kinase pathway. Rho kinase reversibly inhibits transiently expressed Cav3.1 and Cav3.3 channels
and shifts activation and inactivation profiles of Cav3.2 to more depolarized levels. When subjected
to  the  either  Rho  pathway inhibitors,  Rho-associated  kinase  (ROCK),  or  RhoA (Ras  homolog
family GTPase acting on ROCK), the LPA modulation disappeared, promoting the Rho pathway
involvement (Iftinca et al. 2007). It should be noted that the LPA acts through at least two receptors,
LPA1 and LPA3, both of which regulate T-type channels in different manner. LPA1 signal causes
demyelination  and sprouting of  the  dorsal  root  fibers,  induction  of  the  synaptic  reorganisation,
allodynia, and also up-regulates Cav2.1 in DRG and PKCγ in dorsal horn. These effects can be used
to increase our knowledge of the mechanisms characteristic for neuropathic hyperalgesia in the
myelinated sensory A-type fiber.  The LPA3 mediates microglia  activation at  the early stages of
nerve injury and LPA-induced LPA biosynthesis. Although it has been proven that this feed-forward
system is associated with the initiation of neuropathic pain, it is not well known how this system
functions in the later stages of a pain development (Ueda 2011). 
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T-type channels in neuropathic pain
Neuropathic pain resulting from mechanical nerve injury
Prominent role of the small DRG cells in neuropathic pain caused by chronic constriction injury
(CCI)  of  sciatic  nerve,  was  established  by  a  study  showing  that  the  T-type  current  density
significantly increased in layer 4 and 5 of DRG ipsilateral to CCI. This study also showed that  the
voltage  dependency and  activation  kinetics  of  T-type  channels  were  unaffected  (Jagodic  et  al.
2008). Later study, done on a mice suffering from a spinal nerve injury,  confirmed these results and
indicated a significant rise of mRNA and Cav3.2 channel expression in rats suffering from CCI (Yue
et al. 2013).
Initial studies, concentrated on the function of T-type channels in medium-size DRG cells, showed a
mixed results. T-type currents observed in the rats with CCI of peripheral axons showed overall
decrease of T-type currents compared to the sham-operated rats  (McCallum et al.  2003). These
results are in contrast with the data collected by (Yue et al. 2013)and (Jagodic et al. 2008), as they
also  examined  T-type  currents  in  medium-size  DRG cells  and  found  no  significant  change  of
currents in either way.  Possible explanation for this  discrepancy lies in the fact  that  distinctive
subtypes of medium-size DRG cells express different amount of T-type currents, and these studies
examined different populations. This hypothesis is in agreement with other results showing that the
T-type currents appear in both nociceptive  (Jagodic et al. 2007) and non-nociceptive  (Shin et al.
2003) medium size DRG cells.
Research focused on effects of reducing agent L-cysteine in rats suffering from CCI described dose-
dependent increase of hyperalgesia in both CCI and scam-operated rats. However, this increase of
hyperalgesia was much smaller and last for the shorter time in CCI rats. DNTB (oxidizing agent)
decreased L-cysteine induced hyperalgesia  in both groups,  although this  effect was much more
prominent  in  CCI  rats,  suggesting  that  CCI  promotes  reduction  of  the  T-type  channels  and
upregulate  them in this  way causing higher excitability of nociceptive neurons.  Their  data  also
showed that the mibefradil, T-type calcium channel blocker, abolished hyperalgesia in both CCI and
control group of rats (Todorovic et al. 2004). These results were further expanded on by the study
mentioned above. In vivo silencing of Cav3.2 led to the major antinociceptive, anti-hyperalgesic,
and anti-allodynic effects in normal, sham-operated and also CCI rats, altogeter putting another data
on the top of all these results strongly suggesting T-type prominent involvement in neuropathic pain
signalling (Bourinet et al. 2005).
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Diabetic neuropathic pain
Diabetes mellitus type 1 is a chronic, multifactorial disease caused by an autoimmune destruction of
insulin producing B-cells in pancreas. Even though the insulin treatment shows better results in
hyperglycemia  management  than before,  diabetic  patients  are  at  a  high risk of  development  of
peripheral diabetic neuropathy (PDN), promoting  hyperalgesia and allodynia  (Alberti & Zimmet
1998).  Evidence presented above shows that  there is  a strong case for  the connection between
neuropathic pain and the T-type channels. One of the mouse models of diabetes mellitus type 1, Bio
Bred/Worchester rat, develops an immunologically mediated diabetes similar to that of the human
with symptoms of hyperalgesia. BB/W rat  was used for the study exploring relations between the
T-type currents and diabetes.  The results showed that the T-type currents increased threefold in
mixed population of small and medium-size DRG neurons of the BB/W rat (Hall et al. 1995). 
The DRG neurons of rats suffering from streptozotocin (STZ)-induced diabetes express lowered
threshold  for  nociceptor  activation,  increased  spontaneous  neuronal  activity  and  increased
frequency of firing in response to a suprathreshold stimulus. Studies showed that different factors
possibly contribute to the elevated pain sensation, namely up-regulation of HVA Ca2+ channel (Hall
et al. 2001), increased activity of the voltage-gated Na+ channel  (Hong et al. 2004),  altered cell-
specific expression and increased activity of the TRPV1  (Hong & Wiley 2005).  However, later
study  showed  that  effects  of  PDN  hyperalgesia  in  STZ-treated  rats  can  be  reversed  almost
completely by the in vivo silencing of the Cav3.2 channel (Messinger et al. 2009). Although not that
impressive, healthy rats treated with the antisense Cav3.2 also showed significant decrease in pain
sensation.  Interesting thing about this  study is that the T-type currents increased in small  DRG
neurons of diabetic rats with no apparent kinetic alterations of the channel. On the contrary, in the
study focused on medium-size DRG neurons (also showing an up-regulation of the T-type currents
in diabetic rats), depolarizing shift in the steady-state inactivation appeared  (Jagodic et al. 2007).
There  is  not  much  known about  this  discrepancy,  but  probable  explanation  is  that  a  different
regulation process of the T-type currents takes place in distinctive cell types. Although there is not
much known about these regulatory processes, this topic is even more complex when we take the
dorsal horn regulation facilitated by the T-type channels into account. Recent study showed that
regulatory currents in DH caused by the T-type channels vary depending on their  excitatory or
inhibitory  function  in  the  DH of  STZ-treated  rats.  However,  all  of  them are  subjected  to  the
modulation by T-type channel inhibition (Jacus et al. 2012).
Diabetes mellitus type 2, most common type of diabetes, arises from the insulin resistance and is
associated most often with the obesity. Therefore leptin-deficient ob/ob mouse model suffering from
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obesity should be a good subject for testing an influence of the T-type channel blockers on PDN
symptoms. The study made on this mouse model revealed that in hyperalgaetic obese mice, the
mRNA expression of Cav3.2 channel rised threefold with no effect on the expression of other two T-
type channels. The T-type currents were also increased and after treatment with the ECN (novel T-
type channel inhibior), hyperalgesia was significantly alleviated, thus showing connection between
morbid obesity diabetes,  T-type currents and PDN. The observed increase of mRNA expression
cannot account for the different T-type activation kinetics described by the authors of this study.
This  difference  could  be  probably  explained  by  a  different  glycosylation  of  Cav channels  in
hyperglycemic environment,which discussed below  (Latham et al. 2009). 
Recent  studies  addressed  possible  involvement  of  the T-type  calcium channels  glycosylation in
activity and trafficking, both related to the glucosis level of the environment in which the cells were
cultivated. Four conserved asparagin-linked N-glycosylation sites are present in the human Cav3.2
channel:  on N192, N271, N1466, and N1710. The HEK cells  transfected with Cav3.2 channel,
exhibited almost complete loss of the T-type current and decreased expression of the channel when
treated with N-glycosylation inhibitor.  This happened probably due to the decrease in a surface
trafficking, as the glycosylation is crucial for channel folding and also important for the membrane
targeting. Results also showed that an enzymatic removal of N-glycans from the surface-expressed
channels  led to the decrease of T-type  currents.  Altering the glycosylation sites by substituting
asparagin with glutamin in the construct breaks the site and, when expressed in the HEK-293 cells,
causes different N-glycosylation patterns and channel behavior.  Asparagine N192 was identified as
responsible  for  the  steady-state  surface  expression  whereas  asparagine  N1466  reduced  channel
activity while retaining surface expression levels(Weiss et al. 2013).
These results appear to be particularly interesting in research of diabetic neuropathic pain. Increase
of glucose concentration showed a positive effect on channel activity in HEK cells. Further, effects
of the channel de-glycosylation facilitated  by neuraminidase are more pronounced in small DRG
cells expressing T-type channels of diabetic mice than in the same cells of WT mice. Treatment of
diabetic mice with neuraminidase also resulted in decrease of hyperalgia, whereas same treatment in
WT mice had no effect.  From this it can be concluded that modulation of T-type activity by N-
glycosylation  is  physiologicaly  important  and probably  plays  a  significant  role  in  diabetic
neuropathic pain(Orestes et al. 2013). 
Neuropathic pain in cancer treatment
Chemotherapy-evoked neuropathic pain is a major cause of discontinuation of otherwise successful
anti-cancer  chemotherapy.  Paclitaxel  is  an  effective  anti-tumor  suppresor,  but  with  a  strong
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neuropathic side effects caused by its peripheral neurotoxicity. The symptoms of paclitaxel-induced
neuropathy are mostly sensory and peripheral in their nature, consisting of mechanical allodynia,
cold allodynia, ongoing burning pain, tingling and numbness and those symptoms often last for
months or even years after finishing the treatment (Forsyth et al. 1997). These severe side effects
make the paclitaxel-treated mice important experimental model for testing of analgesics decreasing
the  pain  felt  by cancer  patients.  Standard  analgesics  does  not  work  well  on paclitaxel-induced
neuropathic pain, but results show that the ethosuximide, relatively selective T-type calcium channel
antagonist, almost completely reverses the pain induced by paclitaxel treatment. Also, no tolerance
to this analgesic appeared even after prolonged treatment (Flatters & Bennett 2004).
In another study, the researchers demonstrated that the mibefranil, more specific inhibitor of the T-
type  channels  than  ethosuximid,  also  showed  an  inhibitory  effect  on  the  neuropathic  pain  in
paclitaxel-treated  mice.  On  top  of  that,  authors  described  a  similar  inhibitory  effect  of  the
cystathionine-γ-lyase (CSE) blocker  (Okubo et al. 2011). This could be explained by the fact that
CSE creates the  H2S from the L-cysteine(Kamoun 2004), well known up-regulator of the Cav3.2
channel activity. The H2S preferably upregulates Cav3.2, not the other two T-types. This fact can be
explained by looking at the Histidine 191 in the channel. It is well conserved in the Cav3.2, but not
in the Cav3.1 nor Cav3.3, suggesting that His serves as a site for redox modulations, in which the
H2S participates. There is also a good possibility that the H2S gasotransmitter is responsible for the
up-regulation of Cav3.2 rather than an endogenous L-cystein, because the His191-containing linker
is located extracellulary  (Nelson et al. 2007). During experiments done on the paclitaxel-treated
rats, total expression of CSE and  Cav3.2 channels did not change, suggesting that the paclitaxel
possibly induces a higher surface trafficking of the Cav3.2 channel (Okubo et al. 2011).
Conclusion
Recent  results  presented  here  strongly  suggest  the  T-type  channel  involvement  in  the  pain
signalling. Although a lot of aspects and principles, such as lowering the threshold for neuronal
excitability,  neurotransmitter  release,  interactions  with  other  ion  channels  and  intracellular
signalling pathways, regulation of the thalamic T-type burst-firing (Kim et al. 2003), remain to be
further  explored,  it  is  probably safe  to  assume that  the  T-type  channels  can  significantly alter
nociceptive perception. However, further research needs to be done to identify the exact principles
of how these channels relate to the overall pain signalling.
The data collected from animal models of pain are also pointing out that the T-type channel blockers
may serve as a powerful potential analgesics in neuropathic states, because classical analgesics did
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not  show great  success  in  a  neuropathic  pain  management.  However,  these  channel  inhibitors
exhibit different levels of specifity. To achieve analgesic effect, concentration of the ethosuximide,
the  T-channel  blocker  used in  some of  the  studies  presented  above and also  in  a  treatment  of
epilepsy  (Huguenard 2002), have to be high, and at these levels it also blocks other types of ion
channels  (Leresche  et  al.  1998).  Another  popular  and  potent  inhibitor  was  even  approved  for
hypertension  treatment  in  the  US,  but  soon  retracted  as  the  other  ion  channel-blockers  and
cytochrom interactions appeared (Mullins et al. 1998).
Two  T-type  channel  blockers,  with  similar  effects  as  the  TTA-P2  used  in  animal  models  of
neuropathic pain, are currently being tested on humans for safety and pain reduction effects. The
Z994 T-type blocker exhibited positive effects in reducing the pain inflicted by capsaicin and UV
irritation of the skin and continues to the second phase of clinical testing (Lee 2014). The ABT-639
was used in a study performed on the patients suffering from diabetic neuropathic pain with mixed
results. Although a short-term pain relief was observed, long-term effects did not significantly differ
from the patients treated with placebo (Ziegler et al. 2015).
In  conclusion,  the  T-type  channels  seem  to  be  a  good  potential  target  for  the  treatment  of
neuropathic pain. Because of the prominent Cav3.2 expression in the peripheral neurons associated
with  nociceptive  function,  a  future  inhibitor  of  this  T-type  channel  subtype  not  penetrating




Akopian, A.N., Sivilotti, L. & Wood, J.N., 1996. A tetrodotoxin-resistant voltage-gated sodium 
channel expressed by sensory neurons. Nature, 379(6562), pp.257–262. 
Alberti, K.G.M.M. & Zimmet, P.Z., 1998. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional 
report of a WHO Consultation. Diabetic Medicine, 15(7), pp.539–553. 
Almeida, T.F., Roizenblatt, S. & Tufik, S., 2004. REVIEW: Afferent pain pathways: a 
neuroanatomical review. Brain Research, 1000(1), pp.40–56. 
Bao, J., Li, J.J. & Perl, E.R., 1998. Differences in Ca2+ channels governing generation of miniature 
and evoked excitatory synaptic currents in spinal laminae I and II. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 18(21), pp.8740–50. 
Bouhassira, D. et al., 2008. Prevalence of chronic pain with neuropathic characteristics in the 
general population. PAIN, 136(3), pp.380–387. 
Bourinet, E. et al., 2005. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons 
demonstrates its major role in nociception. The EMBO journal, 24(2), pp.315–24. 
Brooks, J. & Tracey, I., 2005. From nociception to pain perception: imaging the spinal and 
supraspinal pathways. Journal of Anatomy, 207(1), pp.19–33. 
Cain, S.M. & Snutch, T.P., 2010. Contributions of T-type calcium channel isoforms to neuronal 
firing. Channels, 4(6), pp.475–482. 
Carbone, E. & Lux, H.D., 1984. A low voltage-activated, fully inactivating Ca channel in vertebrate
sensory neurones. Nature, 310(5977), pp.501–502. 
Cardenas, C.G., Del Mar, L.P. & Scroggs, R.S., 1995. Variation in serotonergic inhibition of 
calcium channel currents in four types of rat sensory neurons differentiated by membrane 
properties. Journal of neurophysiology, 74(5), pp.1870–9. 
Catterall, W.A. et al., 1991. Excitation-contraction coupling in vertebrate skeletal muscle: a tale of 
two calcium channels. Cell, 64(5), pp.871–4. 
Catterall, W.A. et al., 2005. International Union of Pharmacology. XLVIII. Nomenclature and 
Structure-Function Relationships of Voltage-Gated Calcium Channels. Pharmacological Reviews, 
57(4), pp.411–425. 
Catterall, W.A. et al., 1999. Reciprocal regulation of P/Q-type Ca2+ channels by SNAP-25,syntaxin
and synaptotagmin. Nature Neuroscience, 2(11), pp.939–941. 
Cribbs, L.L. et al., 1998. Cloning and Characterization of  1H From Human Heart, a Member of the 
T-Type Ca2+ Channel Gene Family. Circulation Research, 83(1), pp.103–109. 
Crunelli, V., Cope, D.W. & Hughes, S.W., 2006. Thalamic T-type Ca2+ channels and NREM sleep. 
Cell Calcium, 40(2), pp.175–190.
19
18
Djouhri, L. & Lawson, S.N., 2004. REVIEW:Aβ-fiber nociceptive primary afferent neurons: a 
review of incidence and properties in relation to other afferent A-fiber neurons in mammals. Brain 
Research Reviews, 46(2), pp.131–145. 
Drenth, J.P.H. et al., 2007. Mutations in sodium-channel gene SCN9A cause a spectrum of human 
genetic pain disorders. Journal of Clinical Investigation, 117(12), pp.3603–3609. 
Finnerup, N.B. et al., 2015. Pharmacotherapy for neuropathic pain in adults: a systematic review 
and meta-analysis. The Lancet Neurology, 14(2), pp.162–173. 
Flatters, S.J.. & Bennett, G.J., 2004. Ethosuximide reverses paclitaxel- and vincristine-induced 
painful peripheral neuropathy. Pain, 109(1), pp.150–161. 
Flavell, S.W. & Greenberg, M.E., 2008. REVIEW: Signaling mechanisms linking neuronal activity 
to gene expression and plasticity of the nervous system. Annual review of neuroscience, 31, 
pp.563–90. 
Forsyth, P. a. et al., 1997. Prospective study of paclitaxel-induced peripheral neuropathy with 
quantitative sensory testing. Journal of Neuro-Oncology, 35(1), pp.47–53. 
Furukawa, T. et al., 1992. Endothelin-1 enhances calcium entry through T-type calcium channels in 
cultured neonatal rat ventricular myocytes. Circulation Research, 71(5), pp.1242–1253. 
Garrison, S.R. & Stucky, C.L., 2011. The dynamic TRPA1 channel: a suitable pharmacological pain
target? Current pharmaceutical biotechnology, 12(10), pp.1689–97. 
Gold, M.S., Shuster, M.J. & Levine, J.D., 1996. Characterization of six voltage-gated K+ currents 
in adult rat sensory neurons. Journal of neurophysiology, 75(6), pp.2629–46. 
Goldin, A.L. et al., 2000. Nomenclature of Voltage-Gated Sodium Channels. Neuron, 28(2), 
pp.365–368. 
Gu, J.G. & MacDermott, A.B., 1997. Activation of ATP P2X receptors elicits glutamate release 
from sensory neuron synapses. Nature, 389(6652), pp.749–753. 
Hall, K.E. et al., 2001. Impaired inhibitory G-protein function contributes to increased calcium 
currents in rats with diabetic neuropathy. Journal of neurophysiology, 86(2), pp.760–70. 
Hall, K.E., Sima, A.A. & Wiley, J.W., 1995. Voltage-dependent calcium currents are enhanced in 
dorsal root ganglion neurones from the Bio Bred/Worchester diabetic rat. The Journal of 
physiology, (Pt 2), pp.313–22. 
Van Hees, J. & Gybels, J., 1981. C nociceptor activity in human nerve during painful and non 
painful skin stimulation. Journal of neurology, neurosurgery, and psychiatry, 44(7), pp.600–7. 
Hofmann, F. et al., 1994. REVIEW: Annual review of neuroscience 4i contents. JA, 17. 
20
Hong, S. et al., 2004. Early painful diabetic neuropathy is associated with differential changes in 
tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. The 
Journal of biological chemistry, 279(28), pp.29341–50.
Hong, S. & Wiley, J.W., 2005. Early Painful Diabetic Neuropathy Is Associated with Differential 
Changes in the Expression and Function of Vanilloid Receptor 1. Journal of Biological Chemistry, 
280(1), pp.618–627. 
Huguenard, J.R., 2002. Block of T -Type Ca(2+) Channels Is an Important Action of Succinimide 
Antiabsence Drugs. Epilepsy currents / American Epilepsy Society, 2(2), pp.49–52. 
Hui, K., Liu, B. & Qin, F., 2003. Capsaicin activation of the pain receptor, VR1: multiple open 
states from both partial and full binding. J Gen Physiol., 84, pp.2957–2968. 
Chaplan, S.R., Pogrel, J.W. & Yaksh, T.L., 1994. Role of voltage-dependent calcium channel 
subtypes in experimental tactile allodynia. The Journal of pharmacology and experimental 
therapeutics, 269(3), pp.1117–23.
Chemin, J. et al., 2002. Specific contribution of human T-type calcium channel isotypes (alpha(1G),
alpha(1H) and alpha(1I)) to neuronal excitability. The Journal of physiology, 540(Pt 1), pp.3– 14. 
Chemin, J. et al., 2007. Temperature-dependent Modulation of CaV3 T-type Calcium Channels by 
Protein Kinases C and A in Mammalian Cells. Journal of Biological Chemistry, 282(45), pp.32710–
32718.
Chen, C.-C. et al., 1998. A sensory neuron-specific, proton-gated ion channel. Proceedings of the 
National Academy of Sciences, 95(17), pp.10240–10245. 
Choi, S. et al., 2007. Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes, 
brain, and behavior, 6(5), pp.425–31. 
Iftinca, M. et al., 2007. Regulation of T-type calcium channels by Rho-associated kinase. Nature 
Neuroscience, 10(7), pp.854–860. 
Jacus, M.O. et al., 2012. Presynaptic Cav3.2 channels regulate excitatory neurotransmission in 
nociceptive dorsal horn neurons. The Journal of neuroscience : the official journal of the Society for
Neuroscience, 32(27), pp.9374–82. 
Jagodic, M.M. et al., 2007. Cell-specific alterations of T-type calcium current in painful diabetic 
neuropathy enhance excitability of sensory neurons. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 27(12), pp.3305–16. 
Jagodic, M.M. et al., 2008. Upregulation of the T-type calcium current in small rat sensory neurons 
after chronic constrictive injury of the sciatic nerve. Journal of neurophysiology, 99(6), pp.3151–6. 
Jordt, S.-E., Tominaga, M. & Julius, D., 2000. Acid potentiation of the capsaicin receptor 
determined by a key extracellular site. Proceedings of the National Academy of Sciences, 97(14), 
pp.8134–8139. 
21
Kamoun, P., 2004.REVIEW: Endogenous production of hydrogen sulfide in mammals. Amino 
Acids, 26(3), pp.243–254.
Kim, D. et al., 2003. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. 
Science (New York, N.Y.), 302(5642), pp.117–9. 
Kim, J.-A. et al., 2006. Augmentation of Cav3.2 T-type calcium channel activity by 
cAMPdependent protein kinase A. The Journal of pharmacology and experimental therapeutics, 
318(1), pp.230–7. 
Kozlov, A.S. et al., 1999. Distinct kinetics of cloned T-type Ca2 + channels lead to differential Ca2 
+ entry and frequency-dependence during mock action potentials. The European journal of 
neuroscience, 11(12), pp.4149–58. 
Latham, J.R. et al., 2009. Selective T-type calcium channel blockade alleviates hyperalgesia in 
ob/ob mice. Diabetes, 58(11), pp.2656–65. 
Lee, J.H. et al., 1999. Cloning and expression of a novel member of the low voltage-activated Ttype
calcium channel family. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 19(6), pp.1912–21. 
Lee, K.H. et al., 1986. Correlation of cell body size, axon size, and signal conduction velocity for 
individually labelled dorsal root ganglion cells in the cat. The Journal of comparative neurology, 
243(3), pp.335–46. 
Lee, M., 2014. Z944: A first in class T-type calcium channel modulator for the treatment of pain. 
Journal of the Peripheral Nervous System, 19(S2), pp.S11–S12. 
Lenglet, S. et al., 2002. Activation of 5-HT(7) receptor in rat glomerulosa cells is associated with an
increase in adenylyl cyclase activity and calcium influx through T-type calcium channels. 
Endocrinology, 143(5), pp.1748–60. 
Leresche, N. et al., 1998. On the action of the anti-absence drug ethosuximide in the rat and cat 
thalamus. The Journal of neuroscience : the official journal of the Society for Neuroscience, 18(13), 
pp.4842–53. 
Marchettini, P. et al., 2006. REVIEW: Painful Peripheral Neuropathies. Current 
Neuropharmacology, 4(3), pp.175–181. 
McCallum, J.B. et al., 2003. Loss of T-type calcium current in sensory neurons of rats with 
neuropathic pain. Anesthesiology, 98(1), pp.209–16. 
Messinger, R.B. et al., 2009. In vivo silencing of the Ca(V)3.2 T-type calcium channels in sensory 
neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain, 145(1-
2), pp.184–95. 
Mullins, M.E. et al., 1998. Life-threatening interaction of mibefradil and beta-blockers with 
dihydropyridine calcium channel blockers. JAMA, 280(2), pp.157–8. 
22
Nelson, M.T. et al., 2007. Reducing agents sensitize C-type nociceptors by relieving high-affinity 
zinc inhibition of T-type calcium channels. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 27(31), pp.8250–60.
Nelson, M.T. et al., 2005. The endogenous redox agent L-cysteine induces T-type Ca2+ 
channeldependent sensitization of a novel subpopulation of rat peripheral nociceptors. The Journal 
of neuroscience : the official journal of the Society for Neuroscience, 25(38), pp.8766–75. 
Okubo, K. et al., 2011. Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme
reverses paclitaxel-evoked neuropathic hyperalgesia in rats. Neuroscience, 188, pp.148–156. 
Orestes, P. et al., 2013. Reversal of neuropathic pain in diabetes by targeting glycosylation of 
Ca(V)3.2 T-type calcium channels. Diabetes, 62(11), pp.3828–38. 
Peier, A.M. et al., 2002. A TRP Channel that Senses Cold Stimuli and Menthol. Cell, 108(5), 
pp.705–715. 
Perez-Reyes, E. et al., 1998. Molecular characterization of a neuronal low-voltage-activated T-type 
calcium channel. Nature, 391(6670), pp.896–900. 
Perez-Reyes, E., 2003. REVIEW: Molecular physiology of low-voltage-activated t-type calcium 
channels. Physiological reviews, 83(1), pp.117–61. 
Pfeiffer-Linn, C. & Lasater, E.M., 1993. Dopamine modulates in a differential fashion T- and L-type
calcium currents in bass retinal horizontal cells. The Journal of General Physiology, 102(2), pp.277–
294. R.D. 
Treede, R.A. Meyer, J.N.C., 1998. No Ti, Myelinated mechanically insensitive afferents from 
monkey hairy skin: heat-response propertiestle. J. Neurophysiol., (80), pp.1082–1093. 
Ramsey, I.S., Delling, M. & Clapham, D.E., 2006. REVIEW:An introduction to TRP channels. 
Annual Review of Physiology, 68(1), pp.619–647. 
Rangel, A., Sanchez-Armass, S. & Meza, U., 2010. Protein Kinase C-Mediated Inhibition of 
Recombinant T-Type CaV3.2 Channels by Neurokinin 1 Receptors. Molecular Pharmacology, 
77(2), pp.202–210. 
Reuter, H., 1979. Properties of Two Inward Membrane Currents in the Heart. Annual Review of 
Physiology, 41(1), pp.413–424. 
Rossier, M.F. et al., 1995. Inhibition of low threshold calcium channels by angiotensin II in adrenal 
glomerulosa cells through activation of protein kinase C. The Journal of biological chemistry, 
270(25), pp.15137–42. 
Sheng, Z.-H. et al., 1994. Identification of a syntaxin-binding site on N-Type calcium channels. 
Neuron, 13(6), pp.1303–1313. 
Shin, J.-B. et al., 2003. A T-type calcium channel required for normal function of a mammalian 
mechanoreceptor. Nature neuroscience, 6(7), pp.724–30. 
23
Stephen R., W. et al., 1997. The “window” component of the low threshold Ca2+ current produces 
input signal amplification and bistability in cat and rat thalamocortical neurones. Journal of 
Physiology, 505, pp.689–705.
Takahashi, M. et al., 1987. Subunit structure of dihydropyridine-sensitive calcium channels from 
skeletal muscle. Proceedings of the National Academy of Sciences of the United States of America, 
84(15), pp.5478–82. 
Takahashi, T. et al., 2010. Upregulation of Cav3.2 T-type calcium channels targeted by endogenous 
hydrogen sulfide contributes to maintenance of neuropathic pain. PAIN, 150(1), pp.183–191. 
Talley, E.M. et al., 1999. Differential distribution of three members of a gene family encoding low 
voltage-activated (T-type) calcium channels. The Journal of neuroscience : the official journal of the
Society for Neuroscience, 19(6), pp.1895–911. 
Tanabe, T. et al., 1987. Primary structure of the receptor for calcium channel blockers from skeletal 
muscle. Nature, 328(6128), pp.313–318. 
Todorovic, S.M. et al., 2001. Redox Modulation of T-Type Calcium Channels in Rat Peripheral 
Nociceptors. Neuron, 31(1), pp.75–85. 
Todorovic, S.M., Meyenburg, A. & Jevtovic-Todorovic, V., 2004. Redox modulation of peripheral 
T-type Ca2+ channels in vivo: alteration of nerve injury-induced thermal hyperalgesia. Pain, 109(3),
pp.328–339. 
Tominaga, M. et al., 1998. The cloned capsaicin receptor integrates multiple pain-producing stimuli.
Neuron, 21(3), pp.531–43. 
Treede, R.-D. et al., 2008. Neuropathic pain: Redefinition and a grading system for clinical and 
research purposes. Neurology, 70(18), pp.1630–1635. 
Tsakiridou, E. et al., 1995. Selective increase in T-type calcium conductance of reticular thalamic 
neurons in a rat model of absence epilepsy. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 15(4), pp.3110–7. 
Tsien, R.W., Ellinor, P.T. & Horne, W.A., 1991. REVIEW: Molecular diversity of voltagedependent 
Ca2+ channels. Trends in Pharmacological Sciences, 12, pp.349–354. 
Turk, D.C. et al., 2010. Assessment and treatment of psychosocial comorbidities in patients with 
neuropathic pain. Mayo Clinic proceedings, 85(3 Suppl), pp.S42–50. 
Ueda, H., 2011. Lysophosphatidic acid as the initiator of neuropathic pain. Biological & 
pharmaceutical bulletin, 34(8), pp.1154–8. 
Wang, L.-Y. & Kaczmarek, L.K., 1998. High-frequency firing helps replenish the readily releasable 
pool of synaptic vesicles. Nature, 394(6691), pp.384–388. 
Waxman, S.G. et al., 1999.REVIEW: Sodium channels and pain. Proceedings of the National 
Academy of Sciences, 96(14), pp.7635–7639. 
24
Weiss, N. et al., 2012. A Cav3.2/Syntaxin-1A Signaling Complex Controls T-type Channel Activity 
and Low-threshold Exocytosis. Journal of Biological Chemistry, 287(4), pp.2810–2818.
Weiss, N. et al., 2013. Surface expression and function of Cav3.2 T-type calcium channels are 
controlled by asparagine-linked glycosylation. Pflügers Archiv - European Journal of Physiology, 
465(8), pp.1159–1170. 
White, G., Lovinger, D.M. & Weight, F.F., 1989. Transient low-threshold Ca2+ current triggers 
burst firing through an afterdepolarizing potential in an adult mammalian neuron. Proceedings of 
the National Academy of Sciences of the United States of America, 86(17), pp.6802–6. 
Wood, J.N. et al., 2004. REVIEW: Voltage-gated sodium channels and pain pathways. Journal of 
Neurobiology, 61(1), pp.55–71. 
Yang, S.-N. & Berggren, P.-O., 2006. REVIEW: The Role of Voltage-Gated Calcium Channels in 
Pancreatic β-Cell Physiology and Pathophysiology. Endocrine Reviews, 27(6), pp.621–676. 
Yue, J. et al., 2013. Upregulation of T-type Ca2+ channels in primary sensory neurons in spinal 
nerve injury. Spine, 38(6), pp.463–70. 
Zamponi, G.W., 2003. Regulation of Presynaptic Calcium Channels by Synaptic Proteins. Journal 
of Pharmacological Sciences, 92(2), pp.79–83. 
Zhang, Y. et al., 2011. Activation of M3 muscarinic receptors inhibits T-type Ca2+ channel currents 
via pertussis toxin-sensitive novel protein kinase C pathway in small dorsal root ganglion neurons. 
Cellular Signalling, 23(6), pp.1057–1067. 
Ziegler, D. et al., 2015. A randomized double-blind, placebo-, and active-controlled study of       
Ttype calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain, 
156(10), pp.2013–20.
25
